[CAS NO. 976-71-6] Canrenone
PRODUCTS SPECIFICATIONS [976-71-6]
DESCRIPTION [976-71-6]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 340.46 |
| Molecular Formula | C22H28O3 |
| SMILES | C[C@@]12[C@]3(CCC(O3)=O)CC[C@@]1([H])[C@]4([H])C=CC5=CC(CC[C@]5(C)[C@@]4([H])CC2)=O |
1 Publications Citing Use of MCE
Summary
Canrenone (Aldadiene) is an aldosterone antagonist extensively used as a diuretic agent.
IC50 & Target
Target: Aldosterone [1]
In Vitro
Canrenone inhibits the production of eortieosterone, 18-hydroxydesoxyeortieosterone, 18-hydroxycorticosterone and aldosterone in a dose-dependent manner [1] . Canrenone dose-dependently reduces platelet-derived growth factor–induced cell proliferation and motility. Canrenone inhibits the activity of the Na + /H + exchanger 1 induced by platelet-derived growth factor [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Canrenone is the principal active metabolite of Spironolactone in the rat only for a limited period. During chronic treatment a difference developed between the effect of Spironolactone and Canrenone on the RAAS indicating a decrease in the anti-mineralocorticoid activity of Canrenone and an increase in the efficacy of Spironolactone [3] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT02687178 | University of Pavia |
Essential Hypertension
|
October 2010 | Phase 4 |
| NCT03536806 | Institute of Cardiology, Warsaw, Poland |
Atrial Fibrillation, Paroxysmal
|
June 2018 | Phase 4 |
| NCT00403910 | Heart Care Foundation |
Heart Failure
|
September 2002 | Phase 3 |
| NCT04185857 | University Hospital Padova |
Primary Aldosteronism Due to Aldosterone Producing Adenoma
|
January 1, 2018 | |
| NCT03263962 | University of Pavia |
Cardiac Heart Failure Patients
|
July 13, 2017 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : ≥ 100 mg/mL ( 293.72 mM )
* "≥" means soluble, but saturation unknown.
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.9372 mL | 14.6860 mL | 29.3720 mL |
| 5 mM | 0.5874 mL | 2.9372 mL | 5.8744 mL |
| 10 mM | 0.2937 mL | 1.4686 mL | 2.9372 mL |
References
- [1] Erbler HC, et al. On the mechanism of the inhibitory action of the spirolactone SC 9376 (aldadiene) on the production of corticosteroids in rat adrenals in vitro. Naunyn Schmiedebergs Arch Pharmacol. 1973;277(2):139-49.
- [2] Caligiuri A, et al. Antifibrogenic effects of canrenone, an antialdosteronic drug, on human hepatic stellate cells. Gastroenterology. 2003 Feb;124(2):504-20.
- [3] Erbler HC, et al. Effect of spironolactone and its main metabolite canrenone on the renin-angiotensin-aldosterone-system during long-term treatment in rats. Acta Endocrinol (Copenh). 1979 Jan;90(1):147-56.
Synonyms